Authors
Joanne E Kavanagh, Andrew P Hearn, Jaideep Dhariwal, Gráinne d’Ancona, Abdel Douiri, Cris Roxas, Mariana Fernandes, Linda Green, Louise Thomson, Alexandra M Nanzer, Brian D Kent, David J Jackson
Publication date
2021/2/1
Journal
Chest
Volume
159
Issue
2
Pages
496-506
Publisher
Elsevier
Description
Background
Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in reducing asthma exacerbation rates and maintenance oral corticosteroids (mOCSs).
Research Question
What is the real-world effectiveness of benralizumab and what baseline characteristics are associated with response to therapy?
Study Design and Methods
We assessed outcomes in all SEA patients who began benralizumab treatment at our specialist center. At each dosing visit, exacerbation history, mOCS dose, spirometry, and Asthma Control Questionnaire (ACQ6) and Mini-Asthma Quality of Life Questionnaire (mAQLQ) scores were recorded. Response to treatment was defined as a reduction of ≥ 50% in annualized exacerbation rate (AER) or in mOCS dose after 48 weeks of treatment. Super response was defined as zero …
Scholar articles
JE Kavanagh, AP Hearn, J Dhariwal, G d'Ancona… - Chest, 2021
JE Kavanagh, G d'Ancona, M Elstad, L Green… - Chest, 2020